Virchow R (1856). "Die Leukämie". In Virchow R (ed.). Gesammelte Abhandlungen zur Wissenschaftlichen Medizin (in German). Frankfurt: Meidinger. p. 190.
Greer JP, Arber DA, Glader BE, List AF, Means RM, Rodgers GM (2018). "Chapter 74: Diagnosis and Classification of the Acute Leukemias and Myelodysplastic Syndromes". Wintrobe's Clinical Hematology (14th ed.). Wolters Kluwer Health. ISBN978-1-4963-6713-6.
Unless otherwise specified in boxes, reference is: Page 97 in: Sun T (2008). Flow cytometry and immunohistochemistry for hematologic neoplasms. Philadelphia: Lippincott Williams & Wilkins. ISBN978-0-7817-8400-9. OCLC85862340.
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. (March 2016). "Acute myeloid leukaemia". Nature Reviews. Disease Primers. 2 (1): 16010. doi:10.1038/nrdp.2016.10. PMID27159408. S2CID4028327.
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (July 2019). "Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges". Blood Reviews. 36: 70–87. doi:10.1016/j.blre.2019.04.005. PMID31101526. S2CID155630692.
Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, et al. (February 2016). "Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation". Leukemia. 30 (2): 285–294. doi:10.1038/leu.2015.258. PMID26460209. S2CID22100511.
Bizzozero OJ, Johnson KG, Ciocco A (May 1966). "Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time". The New England Journal of Medicine. 274 (20): 1095–1101. doi:10.1056/NEJM196605192742001. PMID5932020.
Yoshinaga S, Mabuchi K, Sigurdson AJ, Doody MM, Ron E (November 2004). "Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies". Radiology. 233 (2): 313–321. doi:10.1148/radiol.2332031119. PMID15375227. S2CID20643232.
Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE (December 2014). "The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1846 (2): 326–341. doi:10.1016/j.bbcan.2014.05.004. PMID24880135.
Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, et al. (September 2005). "Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias". Leukemia. 19 (9): 1567–1572. doi:10.1038/sj.leu.2403876. PMID16049515. S2CID11711013.
Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, et al. (September 1996). "Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party". British Journal of Haematology. 94 (3): 557–573. doi:10.1046/j.1365-2141.1996.d01-1004.x. PMID8790159. S2CID8271000.
Molica M, Perrone S (November 2022). "Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours". Expert Review of Hematology. 15 (11): 973–986. doi:10.1080/17474086.2022.2140137. PMID36271671. S2CID253063457.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (August 1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". British Journal of Haematology. 33 (4): 451–458. doi:10.1111/j.1365-2141.1976.tb03563.x. PMID188440. S2CID9985915.
Duchayne E, Demur C, Rubie H, Robert A, Dastugue N (January 1999). "Diagnosis of acute basophilic leukemia". Leukemia & Lymphoma. 32 (3–4): 269–278. doi:10.3109/10428199909167387. PMID10037024.
Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. (October 1999). "A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties". British Journal of Haematology. 107 (1): 69–79. doi:10.1046/j.1365-2141.1999.01684.x. PMID10520026. S2CID27266593.
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. (December 2000). "Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study". Blood. 96 (13): 4075–4083. doi:10.1182/blood.V96.13.4075. PMID11110676.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, et al. (January 2003). "Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies". Journal of Clinical Oncology. 21 (2): 256–265. doi:10.1200/JCO.2003.08.005. PMID12525517.
Wang ZY (2003). "Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis". Hematology. American Society of Hematology. Education Program. 2003 (1): 1–13. doi:10.1182/asheducation-2003.1.1. PMID14633774. S2CID2788589.
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. (March 2016). "Acute myeloid leukaemia". Nature Reviews. Disease Primers. 2 (1): 16010. doi:10.1038/nrdp.2016.10. PMID27159408. S2CID4028327.
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (July 2019). "Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges". Blood Reviews. 36: 70–87. doi:10.1016/j.blre.2019.04.005. PMID31101526. S2CID155630692.
Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, et al. (February 2016). "Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation". Leukemia. 30 (2): 285–294. doi:10.1038/leu.2015.258. PMID26460209. S2CID22100511.
Bizzozero OJ, Johnson KG, Ciocco A (May 1966). "Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time". The New England Journal of Medicine. 274 (20): 1095–1101. doi:10.1056/NEJM196605192742001. PMID5932020.
Yoshinaga S, Mabuchi K, Sigurdson AJ, Doody MM, Ron E (November 2004). "Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies". Radiology. 233 (2): 313–321. doi:10.1148/radiol.2332031119. PMID15375227. S2CID20643232.
Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE (December 2014). "The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1846 (2): 326–341. doi:10.1016/j.bbcan.2014.05.004. PMID24880135.
Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, et al. (September 2005). "Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias". Leukemia. 19 (9): 1567–1572. doi:10.1038/sj.leu.2403876. PMID16049515. S2CID11711013.
Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, et al. (September 1996). "Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party". British Journal of Haematology. 94 (3): 557–573. doi:10.1046/j.1365-2141.1996.d01-1004.x. PMID8790159. S2CID8271000.
Molica M, Perrone S (November 2022). "Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours". Expert Review of Hematology. 15 (11): 973–986. doi:10.1080/17474086.2022.2140137. PMID36271671. S2CID253063457.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (August 1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". British Journal of Haematology. 33 (4): 451–458. doi:10.1111/j.1365-2141.1976.tb03563.x. PMID188440. S2CID9985915.
Duchayne E, Demur C, Rubie H, Robert A, Dastugue N (January 1999). "Diagnosis of acute basophilic leukemia". Leukemia & Lymphoma. 32 (3–4): 269–278. doi:10.3109/10428199909167387. PMID10037024.
Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. (October 1999). "A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties". British Journal of Haematology. 107 (1): 69–79. doi:10.1046/j.1365-2141.1999.01684.x. PMID10520026. S2CID27266593.
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. (December 2000). "Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study". Blood. 96 (13): 4075–4083. doi:10.1182/blood.V96.13.4075. PMID11110676.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, et al. (January 2003). "Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies". Journal of Clinical Oncology. 21 (2): 256–265. doi:10.1200/JCO.2003.08.005. PMID12525517.
Wang ZY (2003). "Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis". Hematology. American Society of Hematology. Education Program. 2003 (1): 1–13. doi:10.1182/asheducation-2003.1.1. PMID14633774. S2CID2788589.
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. (March 2016). "Acute myeloid leukaemia". Nature Reviews. Disease Primers. 2 (1): 16010. doi:10.1038/nrdp.2016.10. PMID27159408. S2CID4028327.
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (July 2019). "Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges". Blood Reviews. 36: 70–87. doi:10.1016/j.blre.2019.04.005. PMID31101526. S2CID155630692.
Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, et al. (February 2016). "Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation". Leukemia. 30 (2): 285–294. doi:10.1038/leu.2015.258. PMID26460209. S2CID22100511.
Yoshinaga S, Mabuchi K, Sigurdson AJ, Doody MM, Ron E (November 2004). "Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies". Radiology. 233 (2): 313–321. doi:10.1148/radiol.2332031119. PMID15375227. S2CID20643232.
Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, et al. (September 2005). "Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias". Leukemia. 19 (9): 1567–1572. doi:10.1038/sj.leu.2403876. PMID16049515. S2CID11711013.
Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, et al. (September 1996). "Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party". British Journal of Haematology. 94 (3): 557–573. doi:10.1046/j.1365-2141.1996.d01-1004.x. PMID8790159. S2CID8271000.
Molica M, Perrone S (November 2022). "Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours". Expert Review of Hematology. 15 (11): 973–986. doi:10.1080/17474086.2022.2140137. PMID36271671. S2CID253063457.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (August 1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". British Journal of Haematology. 33 (4): 451–458. doi:10.1111/j.1365-2141.1976.tb03563.x. PMID188440. S2CID9985915.
Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. (October 1999). "A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties". British Journal of Haematology. 107 (1): 69–79. doi:10.1046/j.1365-2141.1999.01684.x. PMID10520026. S2CID27266593.
Wang ZY (2003). "Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis". Hematology. American Society of Hematology. Education Program. 2003 (1): 1–13. doi:10.1182/asheducation-2003.1.1. PMID14633774. S2CID2788589.
Hoffbrand AV, Moss PA (2016). "13. Acute myeloid leukaemia". Hoffbrand's essential haematology (Seventh ed.). Chichester, West Sussex. pp. 148–149. ISBN978-1-118-40867-4. OCLC909538759.{{cite book}}: CS1 maint: location missing publisher (link)
Kaushansky K, Lichtman MA, Prchal JT, Levi M, Burns LJ, Linch DC, eds. (2021). "Acute myelogenous leukaemia". Williams hematology (Tenth ed.). New York: McGraw Hill. ISBN978-1-260-46413-9. OCLC1176325543.
Unless otherwise specified in boxes, reference is: Page 97 in: Sun T (2008). Flow cytometry and immunohistochemistry for hematologic neoplasms. Philadelphia: Lippincott Williams & Wilkins. ISBN978-0-7817-8400-9. OCLC85862340.